NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

S&P 500, Eli Lilly and Company, Novo Nordisk A/S Class B, Novo Nordisk A/S. Read 's Market Analysis on Investing.com ...

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...

ORCL gains on strong cloud momentum, while NVO battles obesity headwinds and LIN leans on $10B backlog for growth.

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

Happy Friday to Barchart readers, everywhere. I don’t know what the weather is like where you live, but here in Halifax, on ...

NatWest Group PLC, Pernod Ricard SA, Novo Nordisk A/S Class B, Software AG. Read 's Market Analysis on Investing.com UK.

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...